Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20412468rdf:typepubmed:Citationlld:pubmed
pubmed-article:20412468lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20412468lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:20412468lifeskim:mentionsumls-concept:C0018824lld:lifeskim
pubmed-article:20412468lifeskim:mentionsumls-concept:C1144709lld:lifeskim
pubmed-article:20412468lifeskim:mentionsumls-concept:C0439064lld:lifeskim
pubmed-article:20412468lifeskim:mentionsumls-concept:C0439855lld:lifeskim
pubmed-article:20412468lifeskim:mentionsumls-concept:C0205430lld:lifeskim
pubmed-article:20412468lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:20412468pubmed:issue2lld:pubmed
pubmed-article:20412468pubmed:dateCreated2010-4-23lld:pubmed
pubmed-article:20412468pubmed:abstractTextN-terminal prohormone B-type natriuretic peptide (NT-proBNP) is an important biomarker of prognosis in heart failure and single valve disease. There are limited studies of complex valve disease. Patients with complex valve disease adopt a sedentary lifestyle, so symptoms may be difficult to detect. The authors aimed to determine whether NT-proBNP correlates with the severity of the valve lesion and underlying cardiac function and whether resting NT-proBNP predicts impaired peak VO(2) in patients with complex valve disease. Forty-five patients with complex moderate to severe stenosis or regurgitation of the heart valves underwent a clinical assessment, echocardiography, resting NT-proBNP assessment, and formal cardiopulmonary exercise testing. In a multivariate analysis, the log NT-proBNP (beta=-9.3, SE=1.9, P<.0001) and lean body weight (beta=0.59, SE=0.22, P=.01) were dominant independent predictors of peak VO(2). An NT-proBNP value of 84 pmol/L had 77% sensitivity and 70% specificity to predict impaired functional capacity, peak VO(2) <60% (predicted), area under the curve=0.80. Resting NT-proBNP was the best predictor of peak VO(2) in patients with complex valve disease, while symptoms and ejection fraction are a less reliable guide.lld:pubmed
pubmed-article:20412468pubmed:languageenglld:pubmed
pubmed-article:20412468pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20412468pubmed:citationSubsetIMlld:pubmed
pubmed-article:20412468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20412468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20412468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20412468pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20412468pubmed:statusMEDLINElld:pubmed
pubmed-article:20412468pubmed:issn1751-7133lld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:WhiteHarveyHlld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:StewartRalphRlld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:KerrAndrewAlld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:ZengIreneIlld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:BissessorNayl...lld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:JayasingheRoh...lld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:WeeYong...lld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:LoweBorisBlld:pubmed
pubmed-article:20412468pubmed:authorpubmed-author:ShanahanLukeLlld:pubmed
pubmed-article:20412468pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20412468pubmed:volume16lld:pubmed
pubmed-article:20412468pubmed:ownerNLMlld:pubmed
pubmed-article:20412468pubmed:authorsCompleteYlld:pubmed
pubmed-article:20412468pubmed:pagination50-4lld:pubmed
pubmed-article:20412468pubmed:dateRevised2011-10-19lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:meshHeadingpubmed-meshheading:20412468...lld:pubmed
pubmed-article:20412468pubmed:articleTitleThe role of natriuretic peptides in patients with chronic complex (mixed or multiple) heart valve disease.lld:pubmed
pubmed-article:20412468pubmed:affiliationDepartment of Cardiology, Griffiths University Medical School, Gold Coast Hospital, Gold Coast, Queensland, Australia. naylinbissessor@hotmail.comlld:pubmed
pubmed-article:20412468pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20412468pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed